{"id":"https://openalex.org/W2040729797","doi":"https://doi.org/10.1021/bi802141y","title":"Potent Inhibitors of HIV-1 Integrase Display a Two-Step, Slow-Binding Inhibition Mechanism Which Is Absent in a Drug-Resistant T66I/M154I Mutant","display_name":"Potent Inhibitors of HIV-1 Integrase Display a Two-Step, Slow-Binding Inhibition Mechanism Which Is Absent in a Drug-Resistant T66I/M154I Mutant","publication_year":2009,"publication_date":"2009-01-29","ids":{"openalex":"https://openalex.org/W2040729797","doi":"https://doi.org/10.1021/bi802141y","mag":"2040729797","pmid":"https://pubmed.ncbi.nlm.nih.gov/19178153"},"language":"en","primary_location":{"id":"doi:10.1021/bi802141y","doi":"https://doi.org/10.1021/bi802141y","is_oa":false,"landing_page_url":"https://doi.org/10.1021/bi802141y","pdf_url":null,"source":{"id":"https://openalex.org/S104038378","display_name":"Biochemistry","issn_l":"0006-2960","issn":["0006-2960","1520-4995","1943-295X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biochemistry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110166075","display_name":"Edward P. Garvey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Edward P. Garvey","raw_affiliation_strings":["Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044054259","display_name":"Benjamin J. Schwartz","orcid":"https://orcid.org/0000-0003-3257-9152","observed_orcids":["https://orcid.org/0000-0003-3257-9152"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin Schwartz","raw_affiliation_strings":["Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083690472","display_name":"Margaret J. Gartland","orcid":"https://orcid.org/0000-0002-1200-3706","observed_orcids":["https://orcid.org/0000-0002-1200-3706"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Margaret J. Gartland","raw_affiliation_strings":["Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102113287","display_name":"Scott Lang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott Lang","raw_affiliation_strings":["Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052964137","display_name":"Wendy S. Halsey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wendy Halsey","raw_affiliation_strings":["Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001702938","display_name":"Ganesh M. Sathe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ganesh Sathe","raw_affiliation_strings":["Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002202433","display_name":"H. Luke Carter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Luke Carter","raw_affiliation_strings":["Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5091203226","display_name":"Kurt L. Weaver","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kurt L. Weaver","raw_affiliation_strings":["Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Biological Reagents and Assay Development, GlaxoSmithKline Pharmaceuticals, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, and Department of Biological Reagents and Assay Development and Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426-0989","institution_ids":["https://openalex.org/I4210114143"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5110166075"],"corresponding_institution_ids":["https://openalex.org/I4210114143"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":4.5788,"has_fulltext":false,"cited_by_count":39,"citation_normalized_percentile":{"value":0.94108694,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"48","issue":"7","first_page":"1644","last_page":"1653"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10147","display_name":"Antibiotic Resistance in Bacteria","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1313","display_name":"Molecular Medicine"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hiv-1-integrase-inhibitors","display_name":"HIV-1 integrase inhibitors","score":0.9959999918937683},{"id":"https://openalex.org/keywords/slow-binding-inhibition","display_name":"slow-binding inhibition","score":0.7099999785423279},{"id":"https://openalex.org/keywords/time-dependent-inhibition","display_name":"time-dependent inhibition","score":0.859000027179718},{"id":"https://openalex.org/keywords/preincubation","display_name":"preincubation","score":0.7009999752044678},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.49799999594688416},{"id":"https://openalex.org/keywords/raltegravir","display_name":"raltegravir","score":0.9369999766349792},{"id":"https://openalex.org/keywords/elvitegravir","display_name":"elvitegravir","score":0.9919999837875366},{"id":"https://openalex.org/keywords/binding-kinetics","display_name":"binding kinetics","score":0.6320000290870667}],"concepts":[{"id":"https://openalex.org/C2777068322","wikidata":"https://www.wikidata.org/wiki/Q2740966","display_name":"Elvitegravir","level":5,"score":0.9654297828674316},{"id":"https://openalex.org/C2780404665","wikidata":"https://www.wikidata.org/wiki/Q421552","display_name":"Raltegravir","level":5,"score":0.9479775428771973},{"id":"https://openalex.org/C14430832","wikidata":"https://www.wikidata.org/wiki/Q412550","display_name":"Integrase","level":3,"score":0.8412989377975464},{"id":"https://openalex.org/C57992300","wikidata":"https://www.wikidata.org/wiki/Q2066956","display_name":"Potency","level":3,"score":0.6458899974822998},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5865459442138672},{"id":"https://openalex.org/C2777302000","wikidata":"https://www.wikidata.org/wiki/Q412251","display_name":"Integrase inhibitor","level":5,"score":0.5615564584732056},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.5302217602729797},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.4852707087993622},{"id":"https://openalex.org/C107824862","wikidata":"https://www.wikidata.org/wiki/Q616005","display_name":"Binding site","level":2,"score":0.42870771884918213},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3986590504646301},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.27362972497940063},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2511909306049347},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.20421123504638672},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.11362969875335693},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.07948130369186401},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.06763774156570435},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D001483","descriptor_name":"Base Sequence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007700","descriptor_name":"Kinetics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D017931","descriptor_name":"DNA Primers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019427","descriptor_name":"HIV Integrase","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D019428","descriptor_name":"HIV Integrase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D024882","descriptor_name":"Drug Resistance, Viral","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1021/bi802141y","doi":"https://doi.org/10.1021/bi802141y","is_oa":false,"landing_page_url":"https://doi.org/10.1021/bi802141y","pdf_url":null,"source":{"id":"https://openalex.org/S104038378","display_name":"Biochemistry","issn_l":"0006-2960","issn":["0006-2960","1520-4995","1943-295X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biochemistry","raw_type":"journal-article"},{"id":"pmid:19178153","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19178153","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biochemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8371999859809875,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W1501954618","https://openalex.org/W1689188863","https://openalex.org/W1989276338","https://openalex.org/W1991057723","https://openalex.org/W1991395228","https://openalex.org/W1994293556","https://openalex.org/W2007831756","https://openalex.org/W2010533762","https://openalex.org/W2016408686","https://openalex.org/W2030017358","https://openalex.org/W2039619756","https://openalex.org/W2042656735","https://openalex.org/W2043450267","https://openalex.org/W2053125329","https://openalex.org/W2065208435","https://openalex.org/W2072692397","https://openalex.org/W2077557314","https://openalex.org/W2084595883","https://openalex.org/W2088424911","https://openalex.org/W2109455981","https://openalex.org/W2109881786","https://openalex.org/W2110661303","https://openalex.org/W2117959947","https://openalex.org/W2126573810","https://openalex.org/W2131567422","https://openalex.org/W2137646827","https://openalex.org/W2148026374","https://openalex.org/W2151389386","https://openalex.org/W2154190260","https://openalex.org/W2157746949","https://openalex.org/W2164778451","https://openalex.org/W2165004541","https://openalex.org/W2171711893","https://openalex.org/W2171813035","https://openalex.org/W4249631582"],"related_works":["https://openalex.org/W2055272171","https://openalex.org/W2003191444","https://openalex.org/W2461429282","https://openalex.org/W2057925552","https://openalex.org/W7018267649","https://openalex.org/W2094621241","https://openalex.org/W1966142937","https://openalex.org/W3032152409","https://openalex.org/W2041532523","https://openalex.org/W2050183544"],"abstract_inverted_index":{"Two-metal":[0],"binding":[1,197,203],"HIV-1":[2,10,247],"integrase":[3],"inhibitors":[4,8],"(INIs)":[5],"are":[6],"potent":[7],"of":[9,25,27,37,108,151,161,175,201,222,227,235,241,246],"in":[11,14,183],"vitro":[12],"and":[13,78,137,153,205,229,238],"patients.":[15],"We":[16,216],"report":[17],"here":[18],"for":[19,35,147,213],"the":[20,23,32,115,145,176,207,223,231],"first":[21],"time":[22],"kinetics":[24],"inhibition":[26,152,172,228,237],"integrase-catalyzed":[28],"strand":[29],"transfer.":[30],"First,":[31],"IC(50)":[33,116],"values":[34,113,117],"each":[36],"six":[38,177],"structurally":[39],"distinct":[40],"INIs":[41,89],"decreased":[42],"when":[43],"a":[44,105,120,199,218],"preincubation":[45,186],"was":[46],"included:":[47],"S-1360":[48,122],"(1.3":[49],"microM":[50],"vs":[51,57,63,69,75,82],"0.12":[52],"microM),":[53,124],"L-731,988":[54,125],"(130":[55,61],"nM":[56,62,68,74,81],"9":[58,70],"nM),":[59,65,71,77,127,130,133,136],"L-870,810":[60,128],"4":[64],"raltegravir":[66,131],"(300":[67],"elvitegravir":[72,134],"(90":[73,80],"6":[76,83],"GSK364735":[79,138],"nM).":[84,140],"When":[85],"reactions":[86],"with":[87,92,119],"these":[88],"were":[90,164],"initiated":[91],"integrase,":[93],"progress":[94,189],"curve":[95,190],"analyses":[96],"indicated":[97],"time-dependent":[98,171,236],"inhibition,":[99],"which":[100],"could":[101],"be":[102],"fitted":[103,111],"to":[104,143],"two-step":[106],"mechanism":[107,146],"binding.":[109],"Overall":[110],"K(i)":[112],"matched":[114],"measured":[118,180],"preincubation:":[121],"(0.17":[123],"(34":[126],"(2.4":[129],"(10":[132],"(4.0":[135],"(2.5":[139],"To":[141],"begin":[142],"understand":[144],"this":[148,242],"slow":[149,196,209,225],"onset":[150],"its":[154],"possible":[155,219],"impact":[156],"on":[157],"drug":[158,239],"resistance,":[159],"studies":[160],"resistance":[162,240],"mutations":[163],"initiated.":[165],"T66I/M154I":[166],"exhibited":[167],"little":[168],"if":[169],"any":[170,174],"by":[173,181,188],"INIs,":[178,204],"as":[179],"differences":[182],"potency":[184],"upon":[185],"or":[187],"analysis.":[191],"These":[192],"data":[193],"demonstrate":[194],"that":[195,206],"is":[198,211],"signature":[200],"two-metal":[202],"second":[208,224],"step":[210,226],"required":[212],"full":[214],"potency.":[215],"discuss":[217],"structural":[220],"explanation":[221],"also":[230],"relationship":[232],"between":[233],"loss":[234],"important":[243],"new":[244],"class":[245],"antiretroviral":[248],"drugs.":[249]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}